Patents by Inventor Dani Paul Bolognesi

Dani Paul Bolognesi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR INHIBITION OF MEMBRANE FUSION-ASSOCIATED EVENTS, INCLUDING HIV TRANSMISSION
    Publication number: 20100291680
    Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID NO:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
    Type: Application
    Filed: June 2, 2010
    Publication date: November 18, 2010
    Inventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild, Shawn O'Lin Barney, Dennis Michael Lambert, Stephen Robert Petteway, JR., Alphonse J. Langlois
  • Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids
    Patent number: 7273614
    Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
    Type: Grant
    Filed: October 9, 2002
    Date of Patent: September 25, 2007
    Assignee: Duke University
    Inventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild
  • Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids
    Patent number: 7122190
    Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
    Type: Grant
    Filed: October 9, 2002
    Date of Patent: October 17, 2006
    Assignee: Duke University
    Inventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild, Shawn O'Lin Barney, Dennis Michael Lambert, Stephen Robert Petteway, Alphonse J. Langlois
  • Methods for inhibition of membrane fusion-associated events, including HIV transmission
    Patent number: 6824783
    Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 30, 2004
    Assignee: Duke University
    Inventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild
  • Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids
    Publication number: 20040052820
    Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
    Type: Application
    Filed: October 8, 2002
    Publication date: March 18, 2004
    Applicants: Duke University, Trimeris, Inc.
    Inventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild, Shawn O?apos;Lin Barney, Dennis Michael Lambert, Stephen Robert Petteway, Alphonse J. Langlois
  • Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids
    Publication number: 20040033235
    Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
    Type: Application
    Filed: January 6, 2003
    Publication date: February 19, 2004
    Applicant: Duke University
    Inventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild
  • Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
    Patent number: 6479055
    Abstract: The present invention relates to peptides which exhibit potent anti-viral activity. In particular, the invention relates to methods of using such peptides as inhibitory of respiratory syncytial virus (“RSV”) transmission to uninfected cells. The peptides used in the methods of the invention are homologs of the DP-178 and DP-107 peptides, peptides corresponding to amino acid residues 638 to 673, and to amino acid residues 558 to 595, respectively, of the HIV-1LAI transmembrane protein (TM) gp41.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 12, 2002
    Assignee: Trimeris, Inc.
    Inventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild, Shawn O'Lin Barney, Dennis Michael Lambert, Stephen Robert Petteway, Alphonse J. Langlois
  • Methods for the inhibition of respiratory syncytial virus transmission
    Patent number: 6440656
    Abstract: Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107×178×4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay.
    Type: Grant
    Filed: June 7, 1994
    Date of Patent: August 27, 2002
    Assignee: Trimeris, Inc.
    Inventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild, Shawn O'Lin Barney, Dennis Michael Lambert, Stephen Robert Petteway, Jr.
  • Synthetic peptide inhibitors of HIV transmission
    Patent number: 6133418
    Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP-178 (SEQ ID:1) ptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP-178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
    Type: Grant
    Filed: November 6, 1995
    Date of Patent: October 17, 2000
    Assignee: Duke University
    Inventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild